<a id='d049e39a-c94f-4c82-99c0-8bce010a7715'></a>

NUTRITION SUPPORT CERTIFICATE

<a id='cfefbf72-26fb-4401-a4c9-b22243437fb9'></a>

Fluids & Sodium
Disorders

<a id='11965d6d-6c35-4e5d-a77f-573500394dcb'></a>

<::logo: ASHP
ashp
The logo features the stylized blue text "ashp" in blue with an orange swoosh above the 'h' and 'p', and a registered trademark symbol.::>

<a id='81e53325-9b14-47b5-8863-d65a78e294a5'></a>

CAPTION ERROR

<a id='30de0ff1-ff7b-4b42-a0bc-66433204b260'></a>

Planned by the American Society of Health-System Pharmacists (ASHP) in collaboration with the American Society for Parenteral and Enteral Nutrition (ASPEN).

<a id='36df49d8-c092-4592-b44e-c5924c0089b1'></a>

&#169;2022 American Society of Health-System Pharmacists, Inc. All rights reserved.
No part of this publication may be reproduced or transmitted in any form or by any means, electronic or
mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval
system, without written permission from the American Society of Health-System Pharmacists.

<a id='e38ce2a1-beb1-4f57-ad80-03c4a4c2f1be'></a>

NUTRITION SUPPORT
COMPLICATIONS:
FLUIDS & SODIUM
DISORDERS

Anne M. Tucker, Pharm.D., BCNSP
University of Texas MD Anderson Cancer Center

<::Illustration of a human head and torso receiving intravenous fluids from an IV bag and enteral feeding via a tube, depicted in white outline. : figure::>

NUTRITION SUPPORT
CERTIFICATE

ashp aspen

<a id='798bcf7c-e18d-4d82-bf6b-1019c4444d65'></a>

RELEVANT FINANCIAL
RELATIONSHIP DISCLOSURE

The following persons in control of this activity's content have relevant financial relationships:

- Jay Mirtallo: Fresenius Kabi, consultant

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

<a id='1f13f8e3-5976-4d56-885b-207758b37bff'></a>

As defined by the Standards of Integrity and Independence definition of ineligible company. All relevant
financial relationships have been mitigated prior to the CPE activity.

<a id='6e976e6d-beaa-41a9-9210-ee0a66809435'></a>

NUTRITION SUPPORT
CERTIFICATE

<a id='5e9745a6-93cb-4111-a57d-5ebb909a7097'></a>

# LEARNING OBJECTIVES

*   Analyze patient information to determine the type of fluid & sodium disorder.
*   Describe common etiologies of fluid & sodium disorders and their impact on the nutrition prescription.
*   Design recommendations for the prevention and management of fluid and sodium disorders.

NUTRITION SUPPORT
CERTIFICATE

<a id='7e7f090a-19f8-4af7-97d2-e7247135f55d'></a>

KEY ABBREVIATIONS

*   AdjBW: adjusted body weight
*   BUN: blood urea nitrogen
*   CO2: carbon dioxide
*   ECF: extracellular fluid
*   IBW: ideal body weight
*   ICF: intracellular fluid
*   PN: parenteral nutrition

NUTRITION SUPPORT
CERTIFICATE

<a id='28315dce-2718-4e57-be54-1dd8247be5e5'></a>

# KEY ABBREVIATIONS

*   SIAD: syndrome of inappropriate antidiuresis
*   sOsm: serum osmolality
*   TBW: total body water
*   uNa: urine sodium
*   uOsm: urine osmolality

NUTRITION SUPPORT
CERTIFICATE

<a id='a1ee380f-036f-4d1a-b8ed-c1616394a409'></a>

## SELF-ASSESSMENT #1

*   MN is a 72 year-old female who is admitted to the medicine service for a non-specific complaint of general malaise. On physical exam, she has dry mucous membranes and exhibits poor skin turgor.
*   Past medical history: HTN, osteoarthritis, and hyperlipidemia
*   Home medications: hydrochlorothiazide, aspirin, simvastatin, calcium carbonate, vitamin D
*   Vital signs: BP 96/52, HR 100, RR 14, Temp 37 C
*   Laboratory values: Na 122 mEq/L, K 4 mEq/L, CI 101 mEq/L, CO2 19 mEq/L, BUN 45 mg/dL, Cr 1.5 mg/dL, glucose 115 mg/dL, magnesium 2.4 mg/dL, urine osmolality 450 mOsm/L

NUTRITION SUPPORT
CERTIFICATE

<a id='7ff14278-eb74-4149-a5ed-b621975de052'></a>

SELF-ASSESSMENT #1, CONT.

Which of the following is the most likely diagnosis for this patient's hyponatremia?

A. Hypertonic
B. Hypovolemic hypotonic
C. Euvolemic hypotonic
D. Hypervolemic hypotonic

NUTRITION SUPPORT
CERTIFICATE

<a id='b9dc5873-bd29-4f2f-9a3b-d8a2fa9bb58a'></a>

FLUID AND SODIUM
DISORDERS

NUTRITION SUPPORT
CERTIFICATE

<a id='4b8dde8d-2aa7-486f-b44e-3a864b8abc8a'></a>

TOTAL BODY WATER (TBW)

*   Water content of the body
    *   60% lean body mass for males
    *   50% lean body mass for females
*   Body composition influence on TBW
    *   Water content of fat ~10%
    *   Water content of muscle ~75%

NUTRITION SUPPORT
CERTIFICATE

<a id='b2d284ac-571b-4892-b804-7b25250ef495'></a>

# BODY FLUID DISTRIBUTION

*   Intracellular fluid (ICF)
    *   2/3 total body water
    *   Potassium, magnesium phosphorus
*   Extracellular fluid (ECF)
    *   1/3 total body water
    *   Sodium, chloride, bicarbonate
    *   Subdivisions
        *   3/4 ECF – Interstitial fluid
        *   1/4 ECF – Intravascular fluid
*   Transcellular fluid

<::transcription of the content
: pie chart labeled "%TBW" showing the distribution of body fluids. The chart includes segments for "Interstitial" and "Intravascular" fluids, with a legend indicating "ICF" and "ECF".::>

NUTRITION SUPPORT
CERTIFICATE

<a id='4b201591-309b-4671-b647-dcd63921df30'></a>

BODY FLUID MAINTENANCE

*   Normal cellular function
*   Tight regulation
    *   Serum osmolality (sOsm)
        *   Important determinant of intracellular volume
        *   sOsm = 2 x [Na] + [glucose/18] + [BUN/2.8]
        *   Alterations ⇒ neurological symptoms
    *   Blood volume
        *   Determinant of effective tissue perfusion
        *   Plasma proteins play role in oncotic pressure
        *   Oxygen & nutrient delivery
        *   Metabolic waste removal

NUTRITION SUPPORT
CERTIFICATE

<a id='c0aa90b4-71d2-453a-9737-7d67bf4aa61f'></a>

FLUID REQUIREMENTS

*   Weight and age based
    *   Ages 18-55 years: 35 mL/kg/day
    *   Ages 56-75 years: 30 mL/kg/day
    *   Ages > 75 years: 25 mL/kg/day
    *   Fluid-restricted adults: ≤ 25 mL/kg/day

Canada TW et al. ASPEN Adult Nutrition Support Core Curriculum.
3rd ed. 2017:113-37.

NUTRITION SUPPORT
CERTIFICATE

<a id='1e3adae9-3144-4b02-9283-5c693c3be28c'></a>

FLUID REQUIREMENTS, CONT.

*   Adjusted Holiday-Segar formula
    *   1500 mL for the first 20 kg of body weight, then ADD
        *   Ages <= 50 years: 20 mL per kg of remaining body weight
        *   Ages > 50 years: 15 mL per kg of remaining body weight
*   1 mL/kcal ingested
*   1500-1600 mL/m² per 24 hours

<a id='e48bf804-3ebb-448b-8621-25ee5095bb49'></a>

Canada TW et al. ASPEN Adult Nutrition Support Core Curriculum.
3rd ed. 2017:113-37.

NUTRITION SUPPORT
CERTIFICATE

<a id='0bf0a6d7-6016-4ffe-a95d-e7d7fc2806d2'></a>

ASSESSING FLUID BALANCE

*   Physical exam (mucous membranes, skin turgor, edema)
*   Urine output (0.5-2 mL/kg/hour)
*   Weight changes
*   Temperature
*   Vital signs (blood pressure, heart rate)
*   Intake and output records
*   Insensible losses

NUTRITION SUPPORT
CERTIFICATE

<a id='73a8742f-ee06-42e5-8fcb-e32550380010'></a>

<::logo: Gastrointestinal Losses
GASTROINTESTINAL LOSSES
A brown rectangular banner features white text and a white line-art illustration of a human head with an IV drip and a nasogastric tube.::>

<a id='acdf7869-baee-4aaf-a27c-41d1560ee0cd'></a>

<table id="8-1">
<tr><td id="8-2" rowspan="2">Body Fluid Type</td><td id="8-3" colspan="4">mEq/L</td></tr>
<tr><td id="8-4">Na</td><td id="8-5">Cl</td><td id="8-6">K</td><td id="8-7">HCO3</td></tr>
<tr><td id="8-8">Stomach</td><td id="8-9">60</td><td id="8-a">130</td><td id="8-b">15</td><td id="8-c">0</td></tr>
<tr><td id="8-d">Duodenum</td><td id="8-e">140</td><td id="8-f">80</td><td id="8-g">5</td><td id="8-h">0</td></tr>
<tr><td id="8-i">Pancreas</td><td id="8-j">140</td><td id="8-k">75</td><td id="8-l">5</td><td id="8-m">115</td></tr>
<tr><td id="8-n">Bile</td><td id="8-o">145</td><td id="8-p">100</td><td id="8-q">5</td><td id="8-r">35</td></tr>
<tr><td id="8-s">Ileum</td><td id="8-t">140</td><td id="8-u">104</td><td id="8-v">5</td><td id="8-w">30</td></tr>
<tr><td id="8-x">Colon</td><td id="8-y">60</td><td id="8-z">40</td><td id="8-A">30</td><td id="8-B">0</td></tr>
</table>

<a id='e5a86d90-1748-4268-977c-4ecbce64ab84'></a>

ASPEN Adult Nutrition Support Core Curriculum 3rd edition, 2017:113-137.

<a id='a8d1ac93-d7a6-4b22-9a5c-e09847b9369e'></a>

NUTRITION SUPPORT
CERTIFICATE

<a id='94969f52-4c4b-4d9d-83f6-ae18c960b1a5'></a>

<::logo: Not identified
GASTROINTESTINAL LOSSES
The logo features white outline illustrations of a human head with a tube inserted into the nose/mouth, connected to an IV bag, all set against a brown rectangular background.::>

<a id='ef862032-fff5-4a23-92e3-abf7164aba20'></a>

<table id="8-C">
<tr><td id="8-D" rowspan="2">Body Fluid Type</td><td id="8-E" colspan="4">mEq/L</td></tr>
<tr><td id="8-F">Na</td><td id="8-G">Cl</td><td id="8-H">K</td><td id="8-I">HCO3</td></tr>
<tr><td id="8-J">Stomach</td><td id="8-K">60</td><td id="8-L">130</td><td id="8-M">15</td><td id="8-N">0</td></tr>
<tr><td id="8-O">Duodenum</td><td id="8-P">140</td><td id="8-Q">80</td><td id="8-R">5</td><td id="8-S">0</td></tr>
<tr><td id="8-T">Pancreas</td><td id="8-U">140</td><td id="8-V">75</td><td id="8-W">5</td><td id="8-X">115</td></tr>
<tr><td id="8-Y">Bile</td><td id="8-Z">145</td><td id="8-10">100</td><td id="8-11">5</td><td id="8-12">35</td></tr>
<tr><td id="8-13">Ileum</td><td id="8-14">140</td><td id="8-15">104</td><td id="8-16">5</td><td id="8-17">30</td></tr>
<tr><td id="8-18">Colon</td><td id="8-19">60</td><td id="8-1a">40</td><td id="8-1b">30</td><td id="8-1c">0</td></tr>
</table>

<a id='241fd44b-4cca-4bb8-b0f9-121e49f9c264'></a>

ASPEN Adult Nutrition Support Core Curriculum, 3rd edition, 2017:113-137.

<a id='8c68e89c-8a54-4673-9876-2f0e049fc5dd'></a>

NUTRITION SUPPORT
CERTIFICATE

<a id='0976ad3d-ecb2-4c8d-b680-9c6f4e1bb726'></a>

REPLACEMENT FLUIDS

*   Based upon specific losses
*   Gastric and colonic fluid losses
    *   0.45% NaCl (1/2 Normal Saline) + 10-20 mEq KCI/L
*   Small bowel fluid losses
    *   0.9% NaCl (Normal Saline)
    *   Bicarbonate or acetate-based customized fluid
    *   Balanced crystalloid (e.g., Ringers Lactate)

NUTRITION SUPPORT
CERTIFICATE

<a id='1598e825-27cf-47b8-96ff-66b1cdcfc71c'></a>

NORMAL ELECTROLYTE
CONCENTRATIONS

<table id="9-1">
<tr><td id="9-2">Electrolyte</td><td id="9-3">Adult</td></tr>
<tr><td id="9-4">Sodium</td><td id="9-5">135-145 mEq/L</td></tr>
<tr><td id="9-6">Potassium</td><td id="9-7">3.5-5 mEq/L</td></tr>
<tr><td id="9-8">Chloride</td><td id="9-9">98-108 mEq/L</td></tr>
<tr><td id="9-a">CO₂</td><td id="9-b">23-30 mEq/L</td></tr>
<tr><td id="9-c">Calcium</td><td id="9-d">9-10.5 mg/dL</td></tr>
<tr><td id="9-e">Phosphorus</td><td id="9-f">2.5-4.5 mg/dL</td></tr>
<tr><td id="9-g">Magnesium</td><td id="9-h">1.7-2.4 mg/dL</td></tr>
<tr><td id="9-i" colspan="2">*Variations in lab values exist between institutions</td></tr>
</table>

NUTRITION SUPPORT
CERTIFICATE

<a id='1ec6b493-2bfd-40df-9925-a5468d31d580'></a>

CAPTION ERROR

<a id='b03361c1-1dbb-4120-a810-311b697e341a'></a>

<table id="10-1">
<tr><td id="10-2">Electrolyte</td><td id="10-3">Requirements</td></tr>
<tr><td id="10-4">Sodium</td><td id="10-5">60-100 mEq/day or 1-2 mEq/kg/day</td></tr>
<tr><td id="10-6">Potassium</td><td id="10-7">60-100 mEq/day or 1-2mEq/kg/day</td></tr>
<tr><td id="10-8">Chloride</td><td id="10-9">As needed to maintain acid-base balance</td></tr>
<tr><td id="10-a">Acetate</td><td id="10-b">As needed to maintain acid-base balance</td></tr>
<tr><td id="10-c">Calcium</td><td id="10-d">10-15 mEq/day</td></tr>
<tr><td id="10-e">Phosphorus</td><td id="10-f">20-40 mmol/dayor 0.25-0.5 mmol/kg/day</td></tr>
<tr><td id="10-g">Magnesium</td><td id="10-h">8-20 mEq/day or 0.25-0.5 mEq/kg/day</td></tr>
<tr><td id="10-i" colspan="2">*Consider lower doses for those with renal insufficiency</td></tr>
</table>

<a id='4498d3ff-bac7-418d-a93a-8bf6cf2a6e84'></a>

Mirtallo J et al. JPEN J Parent Enteral Nutr. 2004; 28:S39-S70.

<a id='25f08d59-53cb-4fdc-8562-be73ac932cdb'></a>

NUTRITION SUPPORT
CERTIFICATE

<a id='b7dede06-35b2-465d-85fb-0d195ce4e034'></a>

<::logo: Not identified
ELECTROLYTE DOSING CONSIDERATIONS
The logo features white text on a brown rectangular background, accompanied by a white outline illustration of an IV drip connected to a human head/throat.::>

<a id='e8d4f140-6265-4af0-a93f-f890e5a44964'></a>

▪ Electrolyte disorders
  - Acute (< 48 hours) vs. chronic (> 48 hours)
  - Rate of development, degree of abnormality and/or symptoms
▪ Renal dysfunction
  - Empiric dose - 50% recommended dose
▪ Obesity
  - Adjusted body weight (AdjBW) for weight-based electrolyte dosing
  - AdjBW = [(weight in kg - IBW) x 0.25] + IBW

<a id='febb6d3f-3744-4923-a077-313cc676c4d9'></a>

Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82.

<a id='5cd37089-ff8f-4028-a276-57e06e3cf11b'></a>

NUTRITION SUPPORT
CERTIFICATE

<a id='d4710f52-8be6-406d-91e3-362bf657848f'></a>

# SODIUM

*   Most abundant extracellular cation
*   Normal serum sodium 135-145 mEq/L
*   Primary influence on serum osmolality
*   Changes in serum sodium are due to water balance changes
*   Water flows from areas of lower osmolality to higher osmolality
*   Sodium disorder diagnosis
    *   History and physical
    *   Laboratory analysis (serum, urine)
    *   **Serum osmolality**
    *   **Volume status of the patient**

NUTRITION SUPPORT
CERTIFICATE

<a id='27694181-0bf0-46e6-81b1-e2c227f1284c'></a>

# HYPONATREMIA (NA < 135 MEQ/L)

*   Common electrolyte disorder
    *   28% hospitalized patients
    *   17.2% critically ill patients
*   Up to 6-fold increase in morbidity and mortality
*   Wide symptomatology – neurologic in nature
    *   None
    *   Moderate: headache, nausea, confusion
    *   Severe: vomiting, obtunded, seizures, coma

Mannesse CK et al. Ageing Res Rev. 2013; 12(1):165-73.

NUTRITION SUPPORT
CERTIFICATE

<a id='50940c4e-f9af-413c-93d4-6d5a0f91c842'></a>

<::DIAGNOSTIC ALGORITHM
: flowchart::>
Na correction for hyperglycemia = serum Na + 0.016 (serum glucose - 100)

Hyponatremia (Na < 135 mEq/L)
↓
Serum Osmolality (sOsm)

Branches:
1. Hypertonic (sOsm > 290 mOsm/kg)
   ↓
   Hyperglycemia
   Mannitol infusions

2. Hypotonic (sOsm < 275 mOsm/kg)
   ↓
   Determine volume status of the patient (next slide)

3. Isotonic (sOsm 275-290 mOsm/kg)
   ↓
   Hyperlipidemia
   Hyperproteinemia
<::
Verbalis JG et al. AmJ Med. 2013; 126:S1-S42.
Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82.
NUTRITION SUPPORT
CERTIFICATE

<a id='032be8e0-4e68-4de0-aacb-34b1d720859a'></a>

<::DIAGNOSTIC ALGORITHM
: flowchart::>
<::Hypotonic hyponatremia
(Na < 135 mEq/L, sOsm < 275 mOsm/kg)
: flowchart::>

<::Volume status
of the patient
: flowchart::>

<::From "Volume status of the patient" to three branches:

Branch 1:
Hypovolemia
↓TBW, ↓↓Total body Na

  From "Hypovolemia" to two sub-branches:

  Sub-branch 1.1:
  Renal losses
  uNa >20 mEq/L
  Diuretics (thiazides)
  Osmotic diuresis
  Adrenal insufficiency
  Salt-wasting nephropathy
  Cerebral salt wasting

  Sub-branch 1.2:
  Extrarenal losses
  uNa <20 mEq/L
  Vomiting
  Diarrhea
  Third spacing
  Pancreatitis
  Burns/open wounds
  Excessive sweating

Branch 2:
Euvolemia
↑TBW, ↔Total body Na

  From "Euvolemia" to one sub-branch:

  Sub-branch 2.1:
  uNa >20 mEq/L
  uOsm >100 mOsm/L
  Syndrome of inappropriate antidiuresis (SIAD)
  Hypothyroid
  Glucocorticoid deficiency

Branch 3:
Hypervolemia
↑↑TBW, ↑Total body Na

  From "Hypervolemia" to two sub-branches:

  Sub-branch 3.1:
  uNa >20 mEq/L
  Acute kidney injury
  Chronic kidney disease

  Sub-branch 3.2:
  uNa <20 mEq/L
  Cirrhosis
  Nephrotic syndrome
  Heart failure

NUTRITION SUPPORT
CERTIFICATE
: flowchart::>

<a id='42b570fa-7f18-4094-b615-04a4fcb21346'></a>

<::A brown banner with the text "SIAD" in white on the left side. On the right side, there is a white outline illustration of a human head in profile, with an IV drip bag connected to it, suggesting a medical or healthcare context.
: figure::>

<a id='22096ca4-3d2c-47a6-970f-1fd7e7f5ea06'></a>

Sustained or intermittently elevated antidiuretic hormone (ADH) level inappropriate for osmotic and volume status which normally inhibits ADH secretion

<a id='6ee7f8bb-803e-46ca-be3a-7aceaf899b91'></a>

<table id="13-1">
<tr><td id="13-2">Essential Criteria</td><td id="13-3">Supplemental Criteria</td></tr>
<tr><td id="13-4">Effective sOsm <275 mOsm/kg</td><td id="13-5">Serum uric acid < 0.24 mmol/L (< 4 mg/dL)</td></tr>
<tr><td id="13-6">uOsm > 100 mOsm/kg at some level of decreased</td><td id="13-7">Fractional excretion of uric acid > 12%</td></tr>
<tr><td id="13-8">effective osmolality</td><td id="13-9">Serum urea <3.6 mmol/L (<21.6 mg/dL)</td></tr>
<tr><td id="13-a">Clinical euvolemia</td><td id="13-b">Fractional excretion of urea > 55%</td></tr>
<tr><td id="13-c">uNa > 30 mEq/L (normal sodium & water intake)</td><td id="13-d">Fractional excretion of Na > 0.5%</td></tr>
<tr><td id="13-e">No adrenal, thyroid, pituitary or renal insufficiency</td><td id="13-f">No change in serum Na with 0.9% NaCl administration</td></tr>
<tr><td id="13-g">No recent diuretic use</td><td id="13-h">Na correction with fluid restriction</td></tr>
</table>

<a id='8c4532e2-8e79-4d68-ab8d-78d0786dbd74'></a>

Braun MM et al. Am Fam Physician. 2015; 91(5):299-307.
Kraft MD et al. AmJ Health-Syst Pharm 2005; 62:1663-82.

NUTRITION SUPPORT
CERTIFICATE

<a id='a8645af1-14cf-4ad6-af59-e903279482ec'></a>

# CAUSES OF SIAD

*   Diagnosis of exclusion
*   Causes
    *   Pulmonary (small cell lung cancer, pneumonia, abscess, tuberculosis)
    *   Neurologic (tumors, trauma, meningitis, abscess, subarachnoid hemorrhage, pain, anxiety, nausea)
    *   Hypothyroidism
    *   Medications

Braun MM et al. Am Fam Physician. 2015; 91(5):299-307.
Kraft MD et al. Am J Health-Syst Pharm. 2005; 62:1663-82.

NUTRITION SUPPORT
CERTIFICATE

<a id='9ae21f6f-706d-40b0-82b7-51db9692d5fc'></a>

<::SIAD: MEDICATIONS ASSOCIATED
: An illustration depicting a person receiving medication through an IV drip and a nasal spray.::>

<a id='a170457b-5603-4e7c-a80e-164d77a2dd25'></a>

- Anticancer agents: cyclophosphamide, ifosfamide, vincristine
- Anticonvulsants: carbamazepine, oxcarbazepine
- Antidepressants: SSRIs, TCADs, MAOI, venlafaxine
- Antidiabetic agent: chlorpropamide
- Antipsychotics: phenothiazines
- Miscellaneous: opiates, 3,4-methylenedioxy-methamphetamine (MDMA), non-steroidal anti-inflammatory drugs
- Vasopressin analogs: desmopressin, oxytocin, terlipressin, vasopressin

<a id='0e233f41-e037-4258-b347-1d6f511dfaf3'></a>

Braun MM et al. Am Fam Physician. 2015; 91(5):299-307.
Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82.

NUTRITION SUPPORT
CERTIFICATE

<a id='0df216f7-d596-4719-ad8e-772f094f25cb'></a>

# HYPONATREMIA MANAGEMENT

*   Focus on treatment of underlying cause
*   Discontinuation of hypotonic fluids
*   Replace sodium deficit or water excess
    *   Change in serum Na = (infusate Na – serum Na) / (TBW + 1)
*   Hypertonic saline for symptomatic patients
*   Sodium correction limited to 8-10 mEq per Liter per day
    *   Prevention of central pontine myelinolysis
    *   Gradual onset of neurologic alterations

Braun MM et al. Am Fam Physician. 2015; 91(5):299-307.
Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82.

NUTRITION SUPPORT
CERTIFICATE

<a id='c9622815-d0fc-4731-8c62-5eb7a8d1b5e0'></a>

CAPTION ERROR

<a id='a9e4e492-a17a-4258-8a05-f69a1f361704'></a>

<table id="15-1">
<tr><td id="15-2">Hyponatremia Type</td><td id="15-3">Treatment (plus treat or remove underlying cause)</td></tr>
<tr><td id="15-4">Hypertonic</td><td id="15-5">Insulin (hyperglycemia), discontinue mannitol</td></tr>
<tr><td id="15-6" colspan="2">Hypotonic</td></tr>
<tr><td id="15-7">Hypovolemic</td><td id="15-8">Isotonic fluids (0.9% sodium chloride, lactated ringers), discontinue diuretics, steroids (adrenal insufficiency)</td></tr>
<tr><td id="15-9">Euvolemic</td><td id="15-a">Fluid restriction ± loop diuretics, concentrate PN, ensure at least isotonic fluids, vaptan (SIAD); glucocorticoids (deficiency); thyroid hormone replacement (hypothyroid)</td></tr>
<tr><td id="15-b">Hypervolemic</td><td id="15-c">Sodium and fluid restriction, vaptans, diuretics</td></tr>
</table>

<a id='179f8e36-441a-4fc8-90b4-6a40672e8f42'></a>

Braun MM et al. Am Fam Physician. 2015; 91(5):299-307.
Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82.
---

<a id='0702fd84-f360-4785-b999-49af0b23c935'></a>

NUTRITION SUPPORT
CERTIFICATE

<a id='69338f78-93be-4f34-ad44-7822924638c7'></a>

SELF-ASSESSMENT #2

Which of the following medications increases the risk of developing hypotonic euvolemic hyponatremia?

A. Hydrochlorothiazide
B. Ondansetron
C. Sertraline
D. Spironolactone

NUTRITION SUPPORT
CERTIFICATE

<a id='361646a5-a30e-4cfe-a173-5f537a20d940'></a>

SELF-ASSESSMENT #3

Which of the following sodium concentrations (mEq/L) is the most appropriate choice to use when formulating a parenteral nutrition plan for a patient with heart failure with hyponatremia, shortness of breath, and edema?

option A. 38.5 mEq sodium per Liter: [ ]
option B. 77 mEq sodium per Liter: [ ]
option C. 115 mEq sodium per Liter: [ ]
option D. 154 mEq sodium per Liter: [ ]

NUTRITION SUPPORT
CERTIFICATE

<a id='a77eb05a-ba9d-43a7-a75a-1975b50d6897'></a>

HYPERNATREMIA (NA > 145 MEQ/L)

*   All cases are hypertonic
*   Less common than hyponatremia
    *   1-7.9% hospitalized patients
*   Up to 70% increase in mortality
*   Symptoms – neurologic in nature
    *   Thirst, dry mucus membranes
    *   Mild-moderate: lethargy, weakness, confusion, irritability
    *   Severe: twitching, seizures, coma

<a id='3e9ac45e-c3cc-4f7a-8e82-6d76b9ac4c65'></a>

Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82

<a id='9dd8cd1c-bb55-4701-bb57-51f447b95973'></a>

CAPTION ERROR

<a id='2daf2933-be4a-4702-a5d2-ce033c786bf3'></a>

DIAGNOSTIC ALGORITHM
<::Hypernatremia (Na > 145 mEq/L)

Volume status of the patient

Hypovolemia:
Osmotic / Solute diuresis (hyperglycemia, mannitol, excessive protein provision)
Post-obstructive diuresis
Vomiting
Diarrhea or excess laxative use
Insensible losses

Euvolemia:
Central diabetes insipidus
Nephrogenic diabetes insipidus
Primary polydipsia

Hypervolemia:
Hypertonic saline solutions
Sodium bicarbonate solutions
Hyperaldosteronism
: flowchart::>
Braun MM et al. Am Fam Physician. 2015; 91(5):299-307.
Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82.
NUTRITION SUPPORT
CERTIFICATE

<a id='4d178aaa-8827-42e8-91cc-f638c5e42a34'></a>

# DIABETES INSIPIDUS

*   Condition resulting in imbalance of water in the body due to large amounts of dilute urine excretion
*   Central diabetes insipidus: lack of or decrease in antidiuretic hormone secretion
*   Nephrogenic diabetes insipidus: decreased renal response to antidiuretic hormone
    *   Medication and electrolyte causes of nephrogenic diabetes insipidus
        *   Amphotericin B, cidofovir, foscarnet, demeclocycline, lithium toxicity
        *   Hypercalcemia, hypokalemia

Braun MM et al. Am Fam Physician. 2015; 91(5):299-307.
Kraft MD et al. Am J Health-Syst Pharm. 2005; 62:1663-82.

NUTRITION SUPPORT
CERTIFICATE

<a id='9a1a0dc6-dc54-4901-8959-b59add1f0612'></a>

# HYPERNATREMIA MANAGEMENT

*   Focus on treatment of underlying cause
*   Discontinuation of hypertonic fluids
*   Correct water deficit with hypotonic fluids
    *   Water deficit (L) = TBW x [1 - (serum Na/140)]
    *   Administer 50% in first 24 hours, remainder in next 48-72 hours
*   Isotonic fluids for hemodynamic instability
*   Sodium correction limited to 8-10 mEq per Liter per day
    *   Prevention of cerebral edema

Braun MM et al. Am Fam Physician. 2015; 91(5):299-307.
Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82.

NUTRITION SUPPORT
CERTIFICATE

<a id='e540373b-4624-4da8-bc6b-1bbf6437c2cc'></a>

HYPERNATREMIA MANAGEMENT
<table id="18-1">
<tr><td id="18-2" colspan="2">Hypernatremia Type</td></tr>
<tr><td id="18-3">Hypovolemic</td><td id="18-4">Oral water, enteral water flushes, hypotonic fluids (dextrose 5% in water, 0.45% sodium chloride, addition of sterile water to PN), insulin (hyperglycemia), amino acid dose reduction (solute diuresis)</td></tr>
<tr><td id="18-5">Euvolemic</td><td id="18-6">Desmopressin (central diabetes insipidus) Thiazide diuretics, sodium restriction, calcium or potassium supplementation (nephrogenic diabetes insipidus)</td></tr>
<tr><td id="18-7">Hypervolemic</td><td id="18-8">Loop diuretic, hypotonic fluids (sodium overload), adrenalectomy or spironolactone (hyperaldosteronism)</td></tr>
</table>

<a id='df9bbbc0-c13a-4379-b2ca-e59c8ff6d3a5'></a>

Braun MM et al. Am Fam Physician. 2015; 91(5):299-307.
Kraft MD et al. AmJ Health-Syst Pharm. 2005; 62:1663-82.

<a id='4668c1e4-df58-40d1-b90c-606187ecb351'></a>

NUTRITION SUPPORT
CERTIFICATE

<a id='42c6a93f-46f8-44e2-b177-ea5e619d9729'></a>

SELF-ASSESSMENT #4

*   TT is a 65-year-old patient with enterocutaneous fistula who is on parenteral nutrition providing 28 kcal/kg/day and 3 g protein/kg/day
*   Vital signs: BP 102/62, HR 85, RR 20, Temp 38 C
*   Physical exam: +thirst and dry mucous membranes
*   Basic metabolic panel: Na 154 mEq/L, K 3.2 mEq/L, CI 118 mEq/L, CO₂ 23 mEq/L, BUN 30 mg/dL, Cr 0.9 mg/dL, glucose 82 mg/dL, urine urea nitrogen > 700 mg/dL
*   Input: 2200 mL/day (31 mL/kg/day)
*   Urine output: 5400 mL/ day (3.2 mL/kg/hour)

NUTRITION SUPPORT
CERTIFICATE

<a id='32c6e580-a16f-4528-b9b8-0bef3947e1af'></a>

## SELF-ASSESSMENT #4

Which of the following is the likely type and cause of TT's hypernatremia?

A. Hypervolemic hypernatremia due to excessive fluid administration
B. Nephrogenic diabetes insipidus
C. Syndrome of inappropriate antidiuresis (SIAD)
D. Hypovolemic hypernatremia due to solute diuresis

NUTRITION SUPPORT
CERTIFICATE

<a id='19e9440e-94a3-4cb0-abe3-62285f4713c1'></a>

<::logo: N/A
N/A
A white outline drawing on a brown background depicts a human head in profile with a nasal swab and an IV drip.::>

<a id='5d6f7e4d-9eed-44c3-a2e6-a2545cae31e1'></a>

Self Assessment Questions and Answers

<a id='0b9ec25c-d6f9-4c10-adeb-2ab4c8317ab1'></a>

# SELF-ASSESSMENT #1

*   MN is a 72 year-old female who is admitted to the medicine service for a non-specific complaint of general malaise. On physical exam, she has dry mucous membranes and exhibits poor skin turgor.
*   Past medical history: HTN, osteoarthritis, and hyperlipidemia
*   Home medications: hydrochlorothiazide, aspirin, simvastatin, calcium carbonate, vitamin D
*   Vital signs: BP 96/52, HR 100, RR 14, Temp 37 C
*   Laboratory values: Na 122 mEq/L, K 4 mEq/L, CI 101 mEq/L, CO2 19 mEq/L, BUN 45 mg/dL, Cr 1.5 mg/dL, glucose 115 mg/dL, magnesium 2.4 mg/dL, urine osmolality 450 mOsm/L

<a id='4f5ece54-5a8f-432f-80db-ef62c71d78ed'></a>

NUTRITION SUPPORT
CERTIFICATE

<a id='33cddc38-b61e-4433-9a91-c0025f0841c8'></a>

NUTRITION SUPPORT
CERTIFICATE

<a id='f8e6fe35-393e-4fb7-8168-d0a4b5ee6f55'></a>

SELF-ASSESSMENT #1, CONT.

Which of the following is the most likely diagnosis for this patient's hyponatremia?

A. Hypertonic
B. Hypovolemic hypotonic
C. Euvolemic hypotonic
D. Hypervolemic hypotonic

NUTRITION SUPPORT
CERTIFICATE

<a id='ceee40c9-8345-4a60-a6c5-cf246a552352'></a>

SELF-ASSESSMENT #1, CONT.

Which of the following is the most likely diagnosis for this patient's hyponatremia?

option A. Hypertonic: [ ]
option B. Hypovolemic hypotonic: [x]
option C. Euvolemic hypotonic: [ ]
option D. Hypervolemic hypotonic: [ ]

NUTRITION SUPPORT
CERTIFICATE

<a id='f8b35dfd-beb6-4581-8231-9421b46dc7c1'></a>

SELF-ASSESSMENT #2 <::A white line-art illustration of a human head in profile with a feeding tube inserted through the nose, connected to an IV bag or feeding bag. This visual represents nutrition support.: figure::>
Which of the following medications increases the risk of developing hypotonic
euvolemic hyponatremia?
A. Hydrochlorothiazide
B. Ondansetron
C. Sertraline
D. Spironolactone
NUTRITION SUPPORT
CERTIFICATE

<a id='5bbb55e7-c050-4935-bf60-b43ae6786ade'></a>

## SELF-ASSESSMENT #2

Which of the following medications increases the risk of developing hypotonic euvolemic hyponatremia?

A. Hydrochlorothiazide
B. Ondansetron
C. **Sertraline**
D. Spironolactone

NUTRITION SUPPORT
CERTIFICATE

<a id='4b34e393-d430-47cd-93f9-844797677a51'></a>

SELF-ASSESSMENT #3

Which of the following sodium concentrations (mEq/L) is the most appropriate choice to use when formulating a parenteral nutrition plan for a patient with heart failure with hyponatremia, shortness of breath, and edema?

A. 38.5 mEq sodium per Liter
B. 77 mEq sodium per Liter
C. 115 mEq sodium per Liter
D. 154 mEq sodium per Liter

NUTRITION SUPPORT
CERTIFICATE

<a id='252f7d81-664b-4dc3-87fb-e68fa40da916'></a>

## SELF-ASSESSMENT #3

Which of the following sodium concentrations (mEq/L) is the most appropriate choice to use when formulating a parenteral nutrition plan for a patient with heart failure with hyponatremia, shortness of breath, and edema?

option A. 38.5 mEq sodium per Liter: [x]
option B. 77 mEq sodium per Liter: [ ]
option C. 115 mEq sodium per Liter: [ ]
option D. 154 mEq sodium per Liter: [ ]

NUTRITION SUPPORT CERTIFICATE

<a id='efe4c8b7-311a-4c9c-bb16-8b178482ebfd'></a>

SELF-ASSESSMENT #4

*   TT is a 65-year-old patient with enterocutaneous fistula who is on parenteral nutrition providing 28 kcal/kg/day and 3 g protein/kg/day
*   Vital signs: BP 102/62, HR 85, RR 20, Temp 38 C
*   Physical exam: +thirst and dry mucous membranes
*   Basic metabolic panel: Na 154 mEq/L, K 3.2 mEq/L, CI 118 mEq/L, CO₂ 23 mEq/L, BUN 30 mg/dL, Cr 0.9 mg/dL, glucose 82 mg/dL, urine urea nitrogen > 700 mg/dL
*   Input: 2200 mL/day (31 mL/kg/day)
*   Urine output: 5400 mL/ day (3.2 mL/kg/hour)

NUTRITION SUPPORT
CERTIFICATE

<a id='d2f286db-1a9c-4735-8c68-15183cfbaefb'></a>

## SELF-ASSESSMENT #4

Which of the following is the likely type and cause of TT's hypernatremia?

A. Hypervolemic hypernatremia due to excessive fluid administration
B. Nephrogenic diabetes insipidus
C. Syndrome of inappropriate antidiuresis (SIAD)
D. Hypovolemic hypernatremia due to solute diuresis

NUTRITION SUPPORT
CERTIFICATE

<a id='38b6c60a-bc53-4e0e-853c-e580271cf8c2'></a>

## SELF-ASSESSMENT #4

Which of the following is the likely type and cause of TT's hypernatremia?

option A. Hypervolemic hypernatremia due to excessive fluid administration: [ ]
option B. Nephrogenic diabetes insipidus: [ ]
option C. Syndrome of inappropriate antidiuresis (SIAD): [ ]
option D. Hypovolemic hypernatremia due to solute diuresis: [x]

NUTRITION SUPPORT
CERTIFICATE

<a id='cf11c058-bac1-4b5f-bb12-e1e1171da971'></a>

CONCLUSIONS

*   A thorough history and physical, including medication review, is important for identification and diagnosis of fluid & sodium disorders.
*   Knowledge of causes of fluid & sodium disorders will help in determining appropriate prevention and treatment plan development.
*   Development of a nutrition care plan should be done using a systematic approach including comorbid states, medication therapy, and changes in clinical status.

NUTRITION SUPPORT
CERTIFICATE

<a id='44bd7443-1170-4b1d-b40c-233bff61138d'></a>

REFERENCES

*   Braun MM, Barstow CH, Pyzocha NJ. Diagnosis and management of sodium disorders: hyponatremia and hypernatremia. Am Fam Physician. 2015; 91:299-307.
*   Canada TW, Lord LM. Chapter 7 Fluid, Electrolytes, and Acid-Base Disorders. In: Mueller CM, ed. The A.S.P.E.N. Adult Nutrition Support Core Curriculum. 3rd ed. Maryland: A.S.P.E.N.; 2017:113-37.
*   Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolytes disorders in adult patients in the intensive care unit. Am J Health-Syst Pharm. 2005; 62:1663-82.

NUTRITION SUPPORT
CERTIFICATE

<a id='c5cb51bf-48d5-4702-b981-234d63bcd838'></a>

## REFERENCES, CONT.

*   Mannesse CK, Vondeling AM, van Marum RJ et al. Prevalence of hyponatremia on geriatric wards compared to other settings over four decades: a systematic review. *Ageing Res Rev*. 2013; 12(1):165-173.
*   Mirtallo J, Canada T, Johnson D et al. Safe practices for parenteral nutrition. *JPEN J Parent Enteral Nutr*. 2004; 28:S39-S70.
*   Verbalis JG, Goldsmith, SR, Greenberg A et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. *Am J Med*. 2013; 126:S1-S42.

NUTRITION SUPPORT
CERTIFICATE

<a id='4dad45b2-2dab-4b44-addc-a2aa09751132'></a>

<::A stylized illustration on a brown background depicts medical nutrition support. On the left, a white outline of a human head in profile shows an oral feeding tube extending into the esophagus. On the right, a white outline of an IV bag with tubing is connected to a person's arm. Faint, ghosted versions of these illustrations are visible in the background. Below these illustrations, on a white and brown diagonal band, are two logos: "ashp" and "aspen".
: illustration::>

NUTRITION SUPPORT
CERTIFICATE

<a id='81f6a452-235e-4d5e-ad54-a26ccdcba39d'></a>

<::transcription of the content
: figure::>

Anne M. Tucker, Pharm.D., BCNSP
Clinical pharmacy Specialist
University of Texas MD Anderson Cancer Center
Houston, Texas

Anne M. Tucker is clinical pharmacy specialist at the MD Anderson Cancer
Center, Houston, Texas. She received her BS in Chemistry from the
University of Arkansas, Pharm.D. from the University of Arkansas for Medical
Sciences (UAMS) where she also completed residency training. Dr. Tucker has
over 20 years of experience in critical care and nutrition support practice and
participates in didactic and experiential training of students and post-graduate trainees. Her areas of
interest include fluid and electrolyte disorders, nutrition support in critically ill cancer patients, and the
promotion of safe parenteral nutrition practices.

<a id='2b2f678e-50b4-41d5-bfce-2b01a6b446b4'></a>

Dr. Tucker is currently the Chair of the American Society for Parenteral and Enteral Nutrition (ASPEN) Abstract Review Committee and President of the Texas Gulf Coast ASPEN Chapter. She is also a member and abstract reviewer for American Society of Health-System Pharmacists and Society of Critical Care Medicine. Past leadership includes Chair and member for the Board of Pharmacy Specialties Nutrition Support Specialty Council, Chair and Secretary of the ASPEN Pharmacy Practice Section, Chair of the ASPEN Self-Assessment Committee, Chair for the ASPEN Task Force for Revision of Nutrition Support Pharmacist Standards, and member of the ASPEN Parenteral Nutrition Safety Committee. She is a regular presenter at Clinical Nutrition Week and was most recently involved as an editor and author of the ASPEN Fluid, Electrolytes and Acid-Base Disorders Handbook.

<a id='19de4395-ed5a-4891-a827-513dc02b9a7d'></a>

## Relevant Financial Relationship Disclosure

In accordance with our accreditor's Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

<a id='4a9ffc47-5272-47f5-b48a-d775bcf72877'></a>

The following persons in control of this activity's content have relevant financial relationships:
* Phil Ayers: Fresenius Kabi, consultant and speaker
* David Evans: Fresenius Kabi, consultant and speaker; Abbott Laboratories, consultant and speaker; CVS/OptionCare, consultant; Alcresta, consultant and speaker
* Andrew Mays: Fresenius Kabi, speaker
* Jay Mirtallo: Fresenius Kabi, consultant
* Kris Mogensen: Baxter, speaker; Thrive Rx, advisory board; Pfizer, advisory board

<a id='77b8b272-671f-4fb6-9f67-f0f0c328981f'></a>

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

<a id='193cc645-9b87-49a9-8634-c01ea4d9ad02'></a>

As required by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company, all relevant financial relationships have been mitigated prior to the CPE activity.

<a id='211eb738-b192-4453-b094-e56019317b29'></a>

### Methods and CE Requirements
---
This online activity consists of a combined total of 12 learning modules. Pharmacists and physicians are eligible to receive a total of 20 hours of continuing education credit by completing all 12 modules within this certificate.

<a id='0a3c85d9-6cbc-4e95-a393-21c4f8ab9477'></a>

Participants must participate in the entire activity, complete the evaluation and all required components to claim continuing pharmacy education credit online at ASHP Learning Center http://elearning.ashp.org. Follow the prompts to claim credit and view your statement of credit within 60 days after completing the activity.

<a id='50719092-f550-47b6-ac36-87953d107e56'></a>

**Important Note–ACPE 60 Day Deadline:**
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, check your NABP eProfile account to validate that your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.

<a id='f94e68a5-d97d-448b-9a8c-e2b0560563e1'></a>

## System Technical Requirements
---
Courses and learning activities are delivered via your Web browser and Acrobat PDF. Users should have a basic comfort level using a computer and navigating websites.

<a id='52a26de7-2bd8-4bb2-986d-fc6145ae1b06'></a>

View Frequently Asked Questions for more information.